Haleon completes purchase of 33pc share in Chinese JV.
Haleon announced on Tuesday that it has finalised the acquisition of an additional 33% equity stake in its Chinese joint venture, Tianjin TSKF Pharmaceutical Co (TSKF), from Tianjin Pharmaceutical Group and Tianjin Pharmaceutical Da Ren Tang Group Corporation.
Haleon
31 December 2024 12:30:02
Source: Sharecast
The FTSE 100 consumer goods giant first announced the transaction, valued at CNY 4.465bn (£0.5bn), in September.
It said the acquisition received shareholder approval from DRTG at an extraordinary general meeting in November, with all other necessary regulatory clearances subsequently secured.
Haleon said it expected the transaction to be accretive to earnings per share.
As part of the agreement, Haleon held an option to acquire the remaining 12% stake in TSKF, while DRTG retained the right to sell its remaining interest to Haleon.
At 1212 GMT, shares in Haleon were up 0.56% at 376.2p.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
